Last checked at 11 Apr 2018 17:15
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Director / PDMR Shareholding
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 9 April 2018 options to subscribe for 18,002,568 ordinary shares of £0.01 each in the Company ("Ordinary Shares" and the "Options") were granted to Professor Sir Marc Feldmann, Chairman, Hemogenyx.
The Options were granted as part of a remuneration package. The exercise price of the an Option is £0.035 per Option Share. The Option Shares shall vest in 12 quarterly instalments in arrears on and with effect from the first Vesting Date, being 30 June 2018.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Marc Feldmann
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chairman
| ||||
b)
| Initial notification /Amendment | Amendment to prior notifications 00038962 | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Hemogenyx Pharmaceuticals PLC | ||||
b) | LEI | 2138008L93GYU5GN6179 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Grant of Option
| ||||
b) | Nature of the transaction | Acceptance of a stock option granted as part of a remuneration package
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Date of the transaction | 9 April 2018 | ||||
e) | Place of the transaction | Outside of a trading venue
| ||||
Enquiries:
Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
Sir Marc Feldmann, Chairman | ||
| ||
Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 | |
Christian Dennis | ||
Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 | |
Damon Heath, Erik Woolgar | ||
| ||
Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | |
Lucy Williams/Duncan Vasey | ||
Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
US Media enquiries | ||
Lowell Goodman | Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net | |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.
For more information, visit www.hemogenyx.com.